

(I)

wherein W_1 is =O; and W_2 is



wherein R_3 and R_4 are hydrogen;

X_1 and X_2 are halogen;

R_2 is hydrogen or alkyl;

Y is a saturated or unsaturated C_{2-10} hydrocarbon chain;

A is —COOH or its salt, ester or amide;

R1 is a saturated or unsaturated, straight chain or branched chain lower hydrocarbon;

the bond between C-13 and C-14 positions is double or single bond, and

the steric configuration at C-15 position is R, S or a mixture thereof,

wherein said prostaglandin compound is administered for over 4 weeks,

wherein the treatment induces substantially no serum electrolyte shifting during the term of treatment,

wherein the amount of said prostaglandin compound to be administered is in the range of about 6-48 μg per day, and

wherein the treatment improves quality of life of the subject.

2. The method of claim **1**, wherein said prostaglandin compound is a monocyclic tautomer of formula (I).

3. The method of claim **1**, wherein the amount of said prostaglandin compound to be administered is in the range of about 6-32 μg per day.

4. The method of claim **1**, wherein the amount of said prostaglandin compound to be administered is in the range of about 6-16 μg per day.

5. The method of claim **1**, wherein the amount of said prostaglandin compound to be administered is in the range of about 8-48 μg per day.

6. The method of claim **1**, wherein the prostaglandin compound is administered orally.

7. The method of claim **6**, wherein said prostaglandin compound is administered with an oil solvent as an excipient.

8. The method of claim **7**, wherein said oil solvent is a medium chain fatty acid triglyceride.

9. The method of claim **1**, wherein A is —COOH; Y is $(CH_2)_6$; atoms; R_2 is hydrogen atom; X_1 and X_2 are fluorine atoms; and R_1 is $(CH_2)_3CH_3$.

10. The method of claim **1**, wherein said prostaglandin compound is administered for at least 6 months.

11. The method of claim **1**, wherein said prostaglandin compound is administered for at least 1 year.

12. The method of claim **1**, wherein said human subject is a male human subject.

13. The method of claim **1**, wherein said human subject is a human subject aged 65 years and older.

14. The method of claim **1**, wherein A is —COOH; Y is $(CH_2)_6$; atoms; R_2 is hydrogen atom; X_1 and X_2 are fluorine atoms; and R_1 is $CH_2CH(CH_3)CH_2CH_3$.

15. The method of claim **1**, wherein said human subject is aged 18 years or older.

16. The method of claim **1**, wherein said prostaglandin compound is administered for at least 2 months.

17. The method of claim **1**, wherein the treatment improves quality of life of the subject that is confirmed by SF-36.

* * * * *